Stacker on MSN

Erectile dysfunction prescriptions: Comparing ED medication options

SaveHealth reports that choosing an erectile dysfunction medication involves comparing effectiveness, side effects, and costs ...
Medscape

Phosphodiesterase Inhibitors in Clinical Urology

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...
Business Wire

Global Phosphodiesterase (PDE) Inhibitors Market 2019-2023| Rising Burden of Chronic Diseases to Boost Growth| Technavio

LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...
Medscape

PDE-5 Inhibitor Monotherapy Effective in Treating Lower Urinary Tract Symptoms

May 25, 2006 — Three new studies presented here at the 2006 annual meeting of the American Urological Association support the use of phosphodiesterase-5 (PDE-5) inhibitors for the resolution of lower ...
ascopubs.org

Phosphodiesterase (PDE) inhibitors reduce in vitro proliferation of prostate primary cells but do not interfere with growth of prostate carcinoma cell lines

Serum pharmacoproteomics of erlotinib-treated advanced prostate cancer patients: A SELDI-TOF mass spectrometry analysis No significant financial relationships to disclose. This is an ASCO Meeting ...
Monthly Prescribing Reference

Drug Repurposing Study Shows PDE5 Inhibitors Do Not Reduce Dementia Risk

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.
Labroots

Conflicting Data about use of PDE5 inhibitors in Alzheimer's Disease

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

PDE4 Inhibitors Market Growth Accelerates Amid FDA Approvals, Pipeline Expansion, and Increasing Patient Pool | DelveInsight

PDE4 Inhibitor Commercial success: ZORYVE achieved $166 million in revenue during 2024, representing a remarkable 471% ...
Morningstar

KARMA BIOSCIENCES ANNOUNCES PATENT APPLICATIONS FOR NOVEL NASALLY-ADMINISTERED PDE-5 INHIBITORS

CORVALLIS, Ore., May 8, 2025 /PRNewswire/ -- Karma Biosciences announced today that it has applied for patent protection for two new drug formulations utilizing its proprietary excipient Zenergy™ .
Business Wire

Phosphodiesterase-4 (PDE4) Inhibitor Market to Witness Significant Growth by 2034 Driven by In-depth Industry Analysis and Forecast - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...
Business Insider

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

ROCKVILLE, Md. and SUZHOU, China, Dec. 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...